FRISSORA MARK P 4

4 · BIOADAPTIVES, INC. · Filed Jun 3, 2026

AI-generated summary of this filing

Updated Jun 4, 2026

BIOADAPTIVES (BDPT) Director Mark P. Frissora Receives Preferred Award

What Happened

Mark P. Frissora, a director of BIOADAPTIVES, Inc. (BDPT), was issued 4,717 shares of Series D Convertible Preferred Stock on 2026-06-01. The shares were issued as compensation (transaction reported at $0.00) and are reported as a derivative acquisition (Form 4 code J).

Key Details

Transaction date: 2026-06-01; Form 4 filed: 2026-06-03 (appears timely).
Amount: 4,717 shares of Series D Convertible Preferred Stock, price reported $0.00 (compensation grant).
Conversion: Each Series D preferred is convertible into 100 shares of common stock (i.e., 4,717 preferred → up to 471,700 common), subject to a 4.9% beneficial-ownership limitation.
Conversion restrictions: No conversion may occur until six months after issuance except in a liquidation event; conversion right does not expire. Each preferred share carries 100 votes at stockholder meetings.
Shares owned after transaction: not disclosed in the filing.
Transaction code: J — Other acquisition/disposition (derivative issuance). Footnote F1 confirms the shares were issued as board-service compensation per a February 3, 2025 Board Agreement.

Context

This was a non-cash compensation grant of convertible preferred shares to a director, not an open-market purchase or sale. The securities are derivatives (convertible preferred) with a multi-month conversion lock and an ownership cap, meaning immediate conversion into common shares is restricted and may be limited by the 4.9% threshold. Such grants compensate service and can affect potential voting power and future dilution if converted.

Form 4

Period: 2026-06-01

Director

Transactions

Other
Series D Convertible Preferred Stock
[F2][F1]
2026-06-01+4,717→ 76,271 total
From: 2026-12-01→ Common Stock (471,700 underlying)

Footnotes (2)

[F1]Represents shares of Series D Convertible Preferred Stock issued as compensation for board services pursuant to that certain Board of Directors Agreement, dated February 3, 2025, between the Issuer and the Reporting Person.
[F2]The Reporting Person's shares of Series D Convertible Preferred Stock, par value $0.0001 per share, are convertible into shares of common stock, par value $0.0001 per share, at a ratio of 100 shares of common stock for each share of Series D Convertible Preferred Stock, subject to a 4.9% beneficial ownership limitation. No shares of Series D Convertible Preferred Stock may be converted until six months after the date of issuance, except in the case of liquidation, whereupon the conversion will occur immediately. Each share of Series D Convertible Preferred Stock outstanding at the time of a meeting of stockholders or a solicitation of consent is entitled to 100 votes on matters of the Issuer, without regard to the beneficial ownership limitation. The right to convert does not expire.

Signature

/s/ Mark P. Frissora|2026-06-03

1 file